Please assess the completion status of the following clinical trial:

Trial Title: First-Line FOLFOX-Bevacizumab for Advanced Colorectal Cancer With Wild-Type Ras

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or pathologically confirmed advanced colorectal cancer who received FOLFOX/bevacizumab for first-line treatment of metastatic disease.~2. Patients must not have had disease progression while receiving a minimum of 6 treatments of FOLFOX/bevacizumab. Patients with stable or responding disease on FOLFOX/bevacizumab are eligible. Bevacizumab does not need to be administered with all cycles of FOLFOX.~3. At least 3 weeks since prior FOLFOX/bevacizumab.~4. Wild type ras~5. No potentially curative treatment option.~6. ECOG performance status 0-1~7. Age\>18, not pregnant or breast-feeding~8. Required entry laboratory parameters within 14 days of study entry: Granulocytes ≥ 1500/µl; platelet count ≥ 100,000/µl, Creatinine ≤ 2.0 mg/dl, Bilirubin ≤ 1.5 x upper limit of normal, AST ≤ 3 x upper limit of normal (or ≤ 5 x upper limit of normal for patients with liver metastases), Magnesium \> lower limit of normal~9. Life expectancy of at least 16 weeks~10. Must not have uncontrolled severe, intercurrent illness.~11. No chemotherapy or radiation therapy within last 3 weeks~12. No concurrent anticancer therapy.~13. Signed study-specific consent form prior to study entry~Exclusion Criteria:~1. Prior EGFR inhibitor and prior irinotecan.~2. Clinically significant cardiac disease (e.g., uncontrolled hypertension \[blood pressure of \>150/90 mmHg on medication\], history of myocardial infarction within 6 months,), New York Heart Association (NYHA) Class II or greater congestive heart failure within 6 months, unstable arrhythmia. Patients with an atrial arrhythmia must have this condition well controlled on stable medication. Patients with current or recent (within 6 months) unstable angina are also not eligible.~3. Significant bleeding diathesis or coagulopathy~4. Major surgical procedure within 28 days prior to start of treatment. Port-a-cath placements are allowed.~5. Serious, nonhealing wound, ulcer, or current healing fracture~6. History of cerebral aneurysms or cerebral arteriovenous malformations.~7. Patients with recent (within 12 months) arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), or clinically significant peripheral artery disease should also be excluded.~8. Brain metastases~9. Patients with a history of a gastrointestinal fistula or perforation.~10. Significant infection or other coexistent medical condition that would preclude protocol therapy.~11. Interstitial lung disease~12. Patients who have had an organ transplant~13. Known positive test(s) for HIV infection, hepatitis C virus, acute or chronic active hepatitis B infection~14. Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic.~15. Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years (For example, carcinoma in situ of the breast, bladder and cervix are permissible).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intervention (Type: EXPERIMENTAL): Bevacizumab: 7.5mg/kg, IV over 30-90 minutes every 3 weeks until disease progression.~Panitumumab Dose Level 1: 6mg/kg over 60-120 minutes every 3 weeks until disease progression Dose Level 2: 9mg/kg over 60-120 minutes every 3 weeks until disease progression

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy